6 best eClinical platforms for virtual biotech companies in 2026

Your clinical operations team is three people, maybe five, and every one of them is already stretched across two studies. Your data lives in a CRO's electronic data capture (EDC) login, your patient-reported outcomes sit in a separate ePRO vendor's portal, and nobody owns the reconciliation between them. Viedoc's EDC software was built for exactly this position: a single platform a lean team can configure, launch, and amend without a vendor-side programmer, evaluated here against five other eClinical platforms on module depth, no-code configuration, build speed, and compliance readiness.

You're not choosing a system for a 40-person clinical operations department. You're choosing one your director of clinical operations can run largely alone, that survives a CRO handoff without a migration project, and that scales from a first-in-human study into Phase II without a second procurement cycle.

Enterprise EDC platforms are built around large, dedicated data management functions: change control boards, named validation teams, and study builds that assume weeks of programmer time are available. A virtual biotech doesn't have that bench, and enterprise process overhead erodes runway that should go toward the science instead. The platforms below are reviewed on fit for a team that is small by design, not under-resourced by accident.

Best eClinical solutions: quick comparison

These six eClinical platforms represent the most evaluated options for virtual biotech companies, reviewed across module depth, no-code configuration, build speed, and compliance readiness.

1. Viedoc

Viedoc's EDC software has powered more than 8,000 global studies, and its drag-and-drop Designer means a data manager, not a vendor programmer, owns the study database from first build through every amendment. For a virtual biotech with one asset in flight, that ownership matters more than raw feature count: protocol changes don't wait on a vendor's change-request queue.

Self-service customers can take a database live in as little as one day, and full-service builds typically complete in 8 to 12 weeks, averaging 10 weeks. Viedoc's ePRO software supports 50-plus languages, which matters as soon as a lean team enrolls across more than one country without a local coordinator on the ground.

Viedoc holds ISO 27001 and SOC 2 certifications, is hosted on Microsoft Azure, and maintains a 100% FDA inspection pass rate. Compliance coverage spans FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, and CDISC, with 24/7 support across Viedoc's global offices.

"My experience with Viedoc has been excellent. The database is very customizable and has been able to meet the needs of each of our studies," says Amanda M., Senior Clinical Program Manager.

• Study scale: 8,000-plus global studies; trusted by 500-plus clinical research teams worldwide
• Build speed: Self-service go-live in as little as one day; full-service builds average 10 weeks
• Language support: Available in 50-plus languages for ePRO deployment
• Compliance: FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, ISO 27001, and SOC 2 certified
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Support: 24/7 support and a 100% FDA inspection pass rate

2. Medidata

Medidata offers Rave EDC, an electronic data capture system used to capture, manage, clean, and report trial data across sites, study teams, and regulators. Rave EDC serves as the cornerstone of the wider Medidata Platform, aggregating data from eConsent, eCOA, randomization and trial supply management (RTSM), and imaging sources into a single environment. For early-phase or smaller studies, Medidata offers Rave Lite, a more focused version of Rave tailored to Phase I, Phase IV, and medical device post-market studies, with a flexible pricing model. Rave EDC also supports Rave Companion, which lets sites populate forms directly from electronic health record data. Medidata reports over 700,000 certified site users on the platform, reflecting its scale across large, established sponsor and CRO networks. Study build and configuration on the standard Rave platform generally involve more specialized process requirements than a lighter-weight EDC.

3. Veeva Vault EDC

Veeva offers Vault EDC, part of its Vault Clinical Suite, which unifies electronic data capture with clinical operations, electronic trial master file (eTMF), and clinical trial management system (CTMS) applications on a single cloud platform. Vault EDC is designed to support complex, multi-arm adaptive trials and allows mid-study design amendments without downtime, according to Veeva's product materials. The platform provides a modern interface with personalized dashboards intended to simplify data entry for sites and monitors. Vault EDC connects to other Veeva Clinical Data applications through Veeva Connections, which synchronize enrollment, monitoring, and protocol deviation data across systems without duplicate entry. Because Vault EDC is positioned within the broader Vault Clinical Suite, sponsors evaluating it for a single study or module typically also assess how much of the wider suite they intend to adopt alongside it.

4. Castor EDC

Castor EDC is a cloud-based clinical research platform combining electronic data capture with ePRO, eCOA, and eConsent natively, supporting decentralized and hybrid trial designs without additional middleware. Castor's self-service EDC allows teams to set up studies without training, and its DCT modules can be used independently or together depending on study needs. The platform supports bring-your-own-device and provisioned device models for patient-facing data collection, along with AI-assisted extraction of data from electronic medical records that is reviewed by study staff before entering the database. Castor states its platform is used by pharmaceutical companies, biotech firms, CROs, academic centers, and medical device manufacturers running trials across more than 170 countries. Castor's own materials note the platform does not include a native CTMS, so sponsors requiring one typically pair it with a separate system.

5. Medrio

Medrio provides an EDC and clinical data management system (CDMS) alongside ePRO/eCOA, eConsent, and RTSM in a combined platform, positioned for sponsors and CROs without in-house programming resource. Medrio states its EDC has been used across more than 8,000 clinical trials over more than 20 years, spanning early-phase through post-market studies. According to Medrio's own materials, teams can configure studies without a programmer, using point-and-click tools rather than custom code. The company also offers a dedicated services team of clinical and technical experts to support database build and data management for sponsors that want additional hands-on help. Medrio's product suite is positioned primarily for early-phase, device, and mid-market studies rather than the largest, most complex global Phase III programs.

6. Medable

Medable is a decentralized clinical trial platform built around electronic clinical outcome assessment (eCOA), eConsent, and Televisit, rather than a traditional site-based EDC. Medable's Study Studio offers a no-code builder with a library of more than 400 validated assessment instruments, and the company states its platform operates across more than 80 countries. Medable's architecture is designed to connect into a sponsor's existing EDC, interactive response technology (IRT), and other clinical systems through prebuilt connectors rather than replacing them. This makes Medable a common complement to an EDC platform for sponsors running trials with a significant remote or hybrid patient-facing component, rather than a standalone data management system in its own right.

What to look for in eClinical solutions for virtual biotech companies

Module depth under one login

A virtual biotech that signs separate contracts for EDC, ePRO, and RTSM is effectively running three vendor relationships with three support queues, three sets of credentials, and three separate validation footprints. For a team without a dedicated systems administrator, that fragmentation is a bigger operational risk than any single feature gap.

Best-in-class platforms let a lean team add ePRO or RTSM to an existing EDC contract without a new procurement cycle, with a single sign-on and shared audit trail across modules rather than bolted-together vendors.

Decentralized and hybrid trial support

Virtual biotechs disproportionately run trials with a remote or hybrid patient-facing component, since they often lack the dedicated site network a larger sponsor can lean on. A platform that treats decentralized elements as a bolt-on integration adds exactly the kind of overhead a small team cannot absorb.

The strongest fit connects decentralized clinical trials capability, such as patient-facing ePRO and virtual visits, directly to the same database as site-collected data, with no separate reconciliation step. Overlooking this typically surfaces months later, when remote and site-collected records need manual merging before database lock.

No-code configuration and amendment turnaround

Protocol amendments are a fact of early-phase development, and a platform that requires a vendor programmer for every mid-study change adds cost and delay at the worst possible time. For a virtual biotech, the person making that change is often already managing three other workstreams that week.

Best-in-class platforms let a data manager implement most amendments directly, turned around in days rather than weeks, without downtime to the live database. That is a materially different model from platforms where every eCRF change routes through a vendor's services queue.

Compliance documentation matched to a lean QA function

A virtual biotech's quality assurance function is often one person wearing several hats, not a dedicated computer system validation (CSV) team. Compliance and audit trail depth still have to meet the same bar as a larger sponsor, but the documentation burden needs to fit a much smaller team's bandwidth.

Look for platforms that provide structured, ready-made inspection readiness documentation rather than requiring your QA function to assemble a validation package from scratch for every study.

How to choose the right eClinical solution for virtual biotech companies

Step 1: Define how many vendor relationships you can realistically manage

Before comparing feature lists, count how many separate eClinical contracts, logins, and support queues your current team can maintain alongside its actual clinical work. A platform that scores well on paper but adds a fourth vendor relationship may cost more in coordination time than it saves in capability.

Step 2: Assess your decentralized trial ambitions beyond this study

Consider not just your current protocol, but whether your next one or two studies are likely to include remote assessments, telehealth visits, or home health components. Choosing a platform that only handles today's design can mean a second migration project within 18 months.

Step 3: Evaluate who actually configures and maintains the database

Identify, by name, the person on your team who will build the initial study and implement every amendment afterward. If that person is not a programmer, prioritize platforms with genuine no-code configuration over ones where "self-service" still assumes coding familiarity.

Step 4: Scrutinize the validation documentation your QA function will need to produce

Ask each vendor exactly what inspection-readiness documentation ships with the platform versus what your team has to assemble itself. The gap between those two answers is often the real difference in total cost of ownership for a lean QA function.

Step 5: Choose a platform that scales without a second procurement cycle

The platform you select for a first-in-human study should still fit once your portfolio reaches Phase II, without a full re-validation or a renegotiated contract. Viedoc's modular licensing and no-code Designer are built to scale from a single Phase I asset to a multi-study portfolio on one platform, and you can book a demo to see how that scaling works against your own protocol.

Frequently asked questions

What is the best eClinical platform for virtual biotech companies?

Viedoc's EDC software is the strongest fit for virtual biotech companies, combining no-code study design with unlimited user seats and a 100% FDA inspection pass rate, so a lean clinical operations team can build and amend studies without a vendor programmer. Medidata is a strong alternative for teams anticipating rapid growth into large, complex Phase III programs, though its standard Rave platform is built around more specialized process requirements. Castor EDC is a solid option for virtual biotechs running heavily decentralized studies, since it combines EDC, ePRO, and eConsent natively for remote and hybrid designs.

What should virtual biotech companies look for in an eClinical platform?

Look for module depth under a single login, so ePRO and RTSM can be added without a new vendor contract, alongside genuine no-code configuration that a data manager can operate without programmer support. Native decentralized and hybrid trial capability matters too, since virtual biotechs disproportionately run remote or hybrid patient-facing studies. Finally, check what inspection-readiness documentation ships with the platform, since a lean QA function cannot absorb assembling a validation package from scratch for every study.

How long does it take to build and deploy a clinical study on a modern eClinical platform?

Timelines vary significantly by platform and by how much of the build is self-service versus vendor-managed. On Viedoc, self-service customers can take a database live in as little as one day, while full-service builds typically complete in 8 to 12 weeks, averaging 10 weeks. Larger, more process-heavy EDC implementations, by contrast, are often built around study builds that assume several months of programmer and validation time are available.

How does Viedoc support decentralized and hybrid trials for virtual biotech teams?

Viedoc's ePRO software lets patients report outcomes directly from their own devices, with automated reminders and support for 50-plus languages, all flowing into the same database as site-collected data with no manual reconciliation. Televisits support virtual site visits within the same platform, so a hybrid protocol does not require a separate vendor login for remote assessments. This native integration is a meaningful difference from platforms that connect decentralized elements to the core EDC through a separate integration layer.

What compliance certifications should a virtual biotech look for in an eClinical vendor?

At minimum, look for FDA 21 CFR Part 11 compliance, ICH GCP alignment, GDPR coverage if you enroll in the EU, and HIPAA attestation if you handle US patient data. Security certifications such as ISO 27001 and SOC 2 indicate the vendor has undergone independent review of its information security controls, which sponsors and QA teams frequently ask about during vendor due diligence. Viedoc holds ISO 27001 and SOC 2 certification alongside FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA compliance, with a 100% FDA inspection pass rate across its platform.

Can a small clinical operations team manage an eClinical platform without a dedicated programmer?

Yes, on platforms built for no-code configuration. Viedoc's drag-and-drop Designer allows a data manager to build eCRFs, edit checks, and workflows directly, and to implement most mid-study amendments without vendor involvement or database downtime. This is a meaningfully different operational model from EDC platforms where study builds and amendments are routed through a vendor's professional services team by default.

Making the right eClinical choice for virtual biotech companies

The eClinical software market was estimated at over $11 billion in 2025, growing at roughly 14% annually, and the platforms reviewed here span a wide range of approaches, from large enterprise suites to decentralized-trial specialists that connect into an existing EDC rather than replacing it. The right fit depends on how your team is structured today and how your trial portfolio is likely to look in 18 months.

Organization size and study complexity should drive the decision more than feature checklists. A team without a dedicated data manager needs genuine no-code configuration, while one anticipating growth into multi-country Phase III programs should weigh a platform's ability to scale without a second migration project. Sponsors running primarily US studies tend to weight build speed and cost, while those with EU or APAC enrollment weight compliance credentials more heavily.

Switching vendors mid-portfolio carries a real validation cost, so the platform chosen for a first study tends to become a multi-year commitment by default, and amendment delays compound quietly across a portfolio.

Why Viedoc is the best eClinical choice for virtual biotech companies

If your clinical operations team is small by design, Viedoc's EDC software matches that reality rather than working against it. A no-code Designer means your data manager builds and amends studies directly, self-service go-live can happen in as little as one day, and full-service builds typically complete in 8 to 12 weeks, averaging 10 weeks.

Operationally, Viedoc adds ePRO, RTSM,eTMF, and Televisits to the same login and the same audit trail, with unlimited user seats and no per-user fees, so growing your portfolio does not mean growing your vendor count. Certified designer training and the Viedoc CRO Partner Program are available if you later work through a CRO partner rather than fully in-house.

On compliance, Viedoc holds ISO 27001 and SOC 2 certification, maintains a 100% FDA inspection pass rate, and covers FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA. The Viedoc Inspection Readiness Packet gives a lean QA function ready-made audit documentation instead of a build-from-scratch validation project.

If you want to see how Viedoc's study build speed and compliance documentation hold up against your own protocol, book a demo or request a proposal and we'll walk through it study by study.